Treace Medical Concepts

Treace Medical Concepts EBITDA per Employee

The EBITDA per Employee of Treace Medical Concepts (TMCI) as of Nov 10, 2026 is -125,464.44 USD. In the previous year, EBITDA per Employee was -123,031.11 USD — a change of 1.98% (lower).

EBITDA per Employee

-125,464.44USD

YoY

1.98%

Last updated:

EBITDA per Employee of Treace Medical Concepts is 2025 -125,464.44 USD. EBITDA per Employee of Treace Medical Concepts was 2024 -123,031.11 USD. It decreases by 1.98% lower compared to the previous year.

The Treace Medical Concepts EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-7,855.56 USD
Jan 1, 2020
1,900.00 USD
Jan 1, 2021
-36,688.89 USD
Jan 1, 2022
-87,393.33 USD
Jan 1, 2023
-114,284.44 USD
Jan 1, 2024
-123,031.11 USD
Jan 1, 2025
-125,464.44 USD
The Treace Medical Concepts EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-125,464.44USD+1.98%
-123,031.11USD+7.65%
-114,284.44USD+30.77%
-87,393.33USD+138.20%
-36,688.89USD-2,030.99%
1,900.00USD-124.19%
-7,855.56USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Treace Medical Concepts Stock analysis

What does Treace Medical Concepts do? Treace Medical Concepts Inc is a US-based medical technology company that specializes in the development, manufacturing, and marketing of innovative orthopedic solutions. The company was founded in 2013 by John Treace and is headquartered in Palm Beach Gardens, Florida. The history of Treace Medical Concepts began with a simple idea. Founder John Treace was an orthopedic surgeon who often dealt with patients suffering from a condition called hallux valgus deformity, also known as bunions. The traditional treatment method for this problem was surgery, which was associated with high costs, long recovery times, and a high risk of complications. Treace recognized the need for a more effective and less invasive treatment method and decided to develop a solution. The result of these efforts was the Lapiplasty system, which was FDA approved in 2019. It is a novel procedure for correcting bunions, allowing for three-dimensional alignment of the affected joint. The procedure is quick, safe, and allows patients to walk normally just a few weeks after the surgery. Since the development of the Lapiplasty system, Treace Medical Concepts has expanded its business model and now offers a wide range of orthopedic solutions for various indications. The company has three main divisions: feet and ankles, hands and wrists, and shoulders and elbows. Each division offers a variety of products and solutions to treat a wide range of disorders and conditions. The most well-known products include the Lapiplasty system, as well as the KinetiSense system for motion analysis and the G-Force system for treating tennis elbow. Treace Medical Concepts aims not only to develop innovative products but also to ensure that these products are easily accessible to doctors and patients. The company has formed partnerships with leading medical institutions and distribution partners around the world to ensure that the products can be quickly and effectively used in clinical practice. The company is also dedicated to research and development, investing a significant portion of its revenue in developing new products and technologies. The company has already filed several patents and works closely with doctors and scientists to develop new solutions for a wide range of orthopedic problems. Overall, Treace Medical Concepts has the potential to change the way we treat orthopedic problems. The company has managed to be innovative while keeping the needs and requirements of doctors and patients in mind. With a strong corporate culture and dedicated leadership, Treace Medical Concepts has all the prerequisites to continue to succeed and improve the treatment of orthopedic problems worldwide. Treace Medical Concepts is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Treace Medical Concepts stock

EBITDA per Employee of Treace Medical Concepts is -125,464.44 USD in 2025.

EBITDA per Employee of Treace Medical Concepts changed from -123,031.11 USD to -125,464.44 USD, representing a 1.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Treace Medical Concepts since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Treace Medical Concepts historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Treace Medical Concepts

All Key Metrics — Treace Medical Concepts